How likely are you to recommend Redeye to a friend or colleague?
1
2
3
4
5
6
7
8
9
10
Not likely
Very likely
Not likely
1
2
3
4
5
6
7
8
9
10
Very likely
Message received
Thanks again for rating us!
SEARCH
IDL Biotech: Showing progression in line with investment case
2019-08-23
12:33
LS
Ludvig Svensson
We provide a short research update with the latest financial estimates and valuation following IDL Biotech’s Q2’19 report. We factor in higher gross margins and slightly lower costs related to SG&A in near-term, which has a positive effect on our valuation. Our new base case amounts to SEK 3.8 per share, with a Bull and Bear Case of SEK 7.4 and 1.5 per share, respectively.